ArticleJournal of neurology2024
Cognitive impairment predicts medication discrepancies in Huntington's Disease: patient self-report compared to pharmacy records.
Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Surface-Engineered Precision Nano-Systems for Targeted Treatment of Huntington's Disease: A Review of Recent Advancements.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProper medication reconciliation (= comparing the accuracy of patient-reported medication use with pharmacy records) could prevent potentially dangerous situations such as drug-drug interactions and hospitalization. This is particularly important when patients rely on multiple medications, such as in neurodegenerative disorders like Huntington's Disease (HD). Currently, it is unknown how often medication discrepancies occur in HD patients and which factors contribute to the discrepancies.
objectiveIdentify prognostic factors of medication discrepancies in HD, using patient-reported medication use and local pharmacy records.
methodsWith 134 pre- and manifest HD patients, we performed a multivariable logistic regression analysis with medication discrepancy as dependent variable (pharmacy records as reference value) and sex, CAP score, disease status (pre- or manifest HD), number of concomitant medications taken, presence of an informal caregiver, Unified Huntington's Disease Rating Scale-Total Functioning Capacity, unified cognitive Z-score and Problem Behaviors Assessment-short characteristic scores for depression, anxiety, and apathy as independent variables.
resultsMedication discrepancies were reported frequently, both in premanifest (43.2%) and manifest HD subjects (36.7%). Impaired cognition significantly predicted medication discrepancies (beta = -0.688, SE 0.27, p = 0.011). All other variables were non-significant.
conclusionsRegardless of HD disease status and stage, patient self-reported medication use is not a reliable source, especially in those with impaired cognitive function. The presence of an informal caregiver and the absence of polypharmacy, depression, anxiety and apathy do not influence self-reported medication accuracy. Objective verification of medication use with HD patients' local pharmacy is recommended. TRIAL REGISTRATION NUMBER: ICTRP-NL-OMON55123, HD-med, registered 26-Nov-2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.